MedTrace Logo

Assessing the Integration of Tobacco Cessation Treatment Into Lung Cancer Screening (LCS)

NCT03611881 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 642

Last updated 2024-10-28

Study results available
· View outcomes & findings →

Summary

This randomized controlled trial seeks to evaluate the effectiveness of alternative strategies to integrate smoking cessation interventions into the delivery of low-dose CT (LDCT) lung cancer screening. Using a factorial design, current smokers who enroll will be randomly assigned to receive these interventions: (1) smoking cessation counseling support by telephone or videoconferencing (short duration vs. long duration); (2) nicotine patch treatment (NRT) (short vs.long duration); (3) counselor-facilitated referral (vs. no referral) to an online resource to connect smokers to a community-based social service resources.

Conditions

  • Smoking, Tobacco

Interventions

BEHAVIORAL

Counseling

4 or 8 weeks of behavioral counseling support to promote smoking cessation.

DRUG

Nicotine patch

2 or 8 weeks of nicotine patch given in a tapering dose of 21 mg, 14 mg, 7 mg.

BEHAVIORAL

Community Resource

Counselor-facilitated referral to a community-based program to address social needs.

Sponsors & Collaborators

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Elyse R Park, PhD · Massachusetts General Hospital

  • Nancy A Rigotti, MD · Massachusetts General Hospital

  • Jennifer Haas, MD, MPH · Massachusetts General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-04-01
Primary Completion
2024-01-31
Completion
2024-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03611881 on ClinicalTrials.gov